Evaxion Biotech A/S’s (EVAX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Evaxion Biotech A/S (NASDAQ:EVAX) in a report published on Thursday, Benzinga reports. HC Wainwright currently has a $14.00 price target on the stock.

Evaxion Biotech A/S Price Performance

Shares of Evaxion Biotech A/S stock traded down $0.22 during trading on Thursday, hitting $2.65. 11,754 shares of the stock were exchanged, compared to its average volume of 307,972. The stock has a market cap of $14.34 million, a price-to-earnings ratio of -0.66 and a beta of -0.28. The firm’s 50-day moving average price is $3.13 and its 200 day moving average price is $3.81. Evaxion Biotech A/S has a 12-month low of $2.26 and a 12-month high of $13.61.

Evaxion Biotech A/S (NASDAQ:EVAX) last released its quarterly earnings data on Tuesday, May 28th. The company reported $0.03 earnings per share (EPS) for the quarter. The firm had revenue of $0.05 million for the quarter. As a group, research analysts forecast that Evaxion Biotech A/S will post -0.03 earnings per share for the current year.

Institutional Investors Weigh In On Evaxion Biotech A/S

A hedge fund recently bought a new stake in Evaxion Biotech A/S stock. LM Advisors LLC purchased a new position in shares of Evaxion Biotech A/S (NASDAQ:EVAX) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 337,336 shares of the company’s stock, valued at approximately $231,000. LM Advisors LLC owned approximately 8.90% of Evaxion Biotech A/S at the end of the most recent reporting period. Hedge funds and other institutional investors own 11.04% of the company’s stock.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy that is in pre-clinical stage for the treatment of various cancers.